ANTXAN2 Therapeutics, Inc.

ANTX Stock Price, Valuation & Chart | AN2 Therapeutics, Inc.

Compare

$5.950+0.47 (+8.58%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology ANTX intrinsic value ANTX calculated fair value vs price

Overview Financials Dividends Ratios

ANTX Historical price chart

ANTX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization214.30M

PE Ratio-5.41

EPS-1.1

Trading Volume350.55K

Today's High/Low6.0/5.46

Dividend Yield0.00

52 Week High/Low7.19/1.0

Shares Outstanding36.02M

ANTX Financial Statement

ANTX Analyst ratings

ANTX Analysis & performance metrics

ANTX Company profile

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing…

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

ANTX Management team

Name

Position

Joseph S. Zakrzewski

Co-Founder & Independent Chairman of the Board

Lucy O. Day CPACFO

Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer

Joshua M. Eizen J.D.COO

Chief Legal Officer, Chief Operating Officer & Corporate Secretary

Vince Hernandez

Senior Vice President of Research & Head of Chemistry

Eric E. EasomCEO

Co-Founder, Chief Executive Officer, President & Chairman of the Board

George Harrison Talbot FACP, M.D.

Co-Founder & Senior Clinical Advisor

Michael R. K. Alley Ph.D.

Co-Founder, Senior Vice President of Research Fellow & Head of Biology

Sanjay Chanda Ph.D.

Chief Development Officer

Name

Position

Joseph S. Zakrzewski

Co-Founder & Independent Chairman of the Board

Lucy O. Day CPACFO

Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer

Joshua M. Eizen J.D.COO

Chief Legal Officer, Chief Operating Officer & Corporate Secretary

Vince Hernandez

Senior Vice President of Research & Head of Chemistry

Eric E. EasomCEO

Co-Founder, Chief Executive Officer, President & Chairman of the Board

George Harrison Talbot FACP, M.D.

Co-Founder & Senior Clinical Advisor

Michael R. K. Alley Ph.D.

Co-Founder, Senior Vice President of Research Fellow & Head of Biology

Sanjay Chanda Ph.D.

Chief Development Officer

Management Team

Joseph S. Zakrzewski

Co-Founder & Independent Chairman of the Board

Lucy O. Day CPACFO

Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer

Joshua M. Eizen J.D.COO

Chief Legal Officer, Chief Operating Officer & Corporate Secretary

Vince Hernandez

Senior Vice President of Research & Head of Chemistry

Eric E. EasomCEO

Co-Founder, Chief Executive Officer, President & Chairman of the Board

George Harrison Talbot FACP, M.D.

Co-Founder & Senior Clinical Advisor

Michael R. K. Alley Ph.D.

Co-Founder, Senior Vice President of Research Fellow & Head of Biology

Sanjay Chanda Ph.D.

Chief Development Officer

Management

Joseph S. Zakrzewski

Co-Founder & Independent Chairman of the Board

Lucy O. Day CPACFO

Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer

Joshua M. Eizen J.D.COO

Chief Legal Officer, Chief Operating Officer & Corporate Secretary

Vince Hernandez

Senior Vice President of Research & Head of Chemistry

Eric E. EasomCEO

Co-Founder, Chief Executive Officer, President & Chairman of the Board

George Harrison Talbot FACP, M.D.

Co-Founder & Senior Clinical Advisor

Michael R. K. Alley Ph.D.

Co-Founder, Senior Vice President of Research Fellow & Head of Biology

Sanjay Chanda Ph.D.

Chief Development Officer

Total 8 executives

ANTX Frequently asked questions

What is AN2 Therapeutics, Inc. (ANTX) Stock Price?

Current stock price of AN2 Therapeutics, Inc. (ANTX) stock is $5.950. The stock price is +8.58% higher in the session. The intraday range can be seen from this page. Volume of AN2 Therapeutics, Inc. (ANTX) stock is 350.55K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the AN2 Therapeutics, Inc. (ANTX) stock price going up or down today?

The stock price of AN2 Therapeutics, Inc. (ANTX) can change with earnings, company news, and overall market sentiment. AN2 Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the AN2 Therapeutics, Inc. stock expensive at its current price?

Whether AN2 Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ANTX on this page is -5.41. EPS on this page is -1.10. Compare those figures with peers and growth expectations before deciding if the current AN2 Therapeutics, Inc. price is justified.

How has the stock price of AN2 Therapeutics, Inc. (ANTX) performed historically?

Historical performance for AN2 Therapeutics, Inc. (ANTX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ANTX reacted to past earnings and market events.

Should I buy AN2 Therapeutics, Inc. (ANTX) stock, at this price?

Buying AN2 Therapeutics, Inc. (ANTX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.